18.66 USD
↗ 0.25 (1.36%)AT CLOSE (03:59 PM EDT)
Denali Therapeutics Inc. Common Stock
DNLINASDAQ • USD
18.47
↘ 0.19 (1.04%)
POST MARKET (AS OF 07:55 PM EDT)
Post Market
AS OF 07:55 PM EDT
18.47
↘ 0.19 (1.04%)
Market: CLOSED
DNLI is currently priced at $18.67. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Key drivers include a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, DNLI is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Oct 26, 2026.
Open?$18.50
High?$18.67
Low?$18.35
Prev. Close?$18.41
Volume?726.0K
Avg. Volume?1.9M
VWAP?$18.55
Rel. Volume?0.38x
Bid / Ask
Bid?$14.62 × 100
Ask?$22.23 × 100
Spread?$7.61
Midpoint?$18.43
Valuation & Ratios
Market Cap?2.9B
Shares Out?159.8M
Float?133.1M
Float %?83.3%
P/E Ratio?N/A
P/B Ratio?3.52
EPS?-$3.21
Dividend?0.00%
Ex-Dividend?N/A
RelatedBEAM
News
Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Employees
507
Market Cap
2.9B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2017-12-08
Address
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 866-8547
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 866-8547
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?30
Momentum?77
Short Sent.?54
Piotroski F-Score?0/9Weak
Altman Z-Score?1.82Grey
Confidence?54%Low
Short InterestHigh
Short % of Float?11.62%High
Short Interest?15.5M
Days to Cover?8.1
Free Float133.1M
Avg Daily Volume1.9M
Settlement Date2026-10-15
Financial Health
Current Ratio?8.37Strong
Quick Ratio?8.32Strong
Cash Ratio?2.24Strong
Debt/Equity?0.01Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.52FAIR▾
Peers50
S&P49
P/S?816.53HIGH▾
Peers50
S&P3
P/FCF?N/A▾
EV/EBITDA?-5.2CHEAP▾
S&P97
EV/Sales?762.14HIGH▾
Peers50
S&P3
Returns & Efficiency
ROE?-61.4%WEAK▾
S&P3
ROA?-44.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-437457000
Enterprise Value?$2.7B
Fundamentals ratios updated end of day